Penalizing FDA for Expanding Mifepristone Access 4

Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies Appropriations Act, 2024. Good (R-VA) amendment to reduce to $1 the salary of the Director of New Drugs at the FDA as part of ongoing attempts to limit access to mifepristone by targeting trained experts for their scientific and medical decision making. A vote for reproductive freedom was against the amendment.

This measure negatively impacts reproductive freedom.

September 27, 2023

Voting Record

State/Territory:

Chamber:

Party:

Votes:

Name	State/Territory	Chamber	Party	How they voted yea Vote for/in favor of nay Vote against — Abstained, absent, ineligible, present, resigned or deceased L Leader switched vote to preserve right to file a motion to reconsider S The speaker exercised their discretion not to vote
Paul Tonko	New York	House	Democratic	nay
Norma Torres	California	House	Democratic	nay
Ritchie Torres	New York	House	Democratic	nay
Lori Trahan	Massachusetts	House	Democratic	nay
David Trone	Maryland	House	Democratic	nay
Mike Turner	Ohio	House	Republican	nay
Lauren Underwood	Illinois	House	Democratic	nay
David Valadao	California	House	Republican	nay
Jefferson Van Drew	New Jersey	House	Republican	yea
Beth Van Duyne	Texas	House	Republican	yea
Derrick Van Orden	Wisconsin	House	Republican	yea
Juan Vargas	California	House	Democratic	nay
Gabe Vasquez	New Mexico	House	Democratic	nay
Marc Veasey	Texas	House	Democratic	nay
Nydia Velázquez	New York	House	Democratic	nay
Ann Wagner	Missouri	House	Republican	nay
Tim Walberg	Michigan	House	Republican	yea
Michael Waltz	Florida	House	Republican	yea
Debbie Wasserman Schultz	Florida	House	Democratic	nay
Maxine Waters	California	House	Democratic	nay
Bonnie Watson Coleman	New Jersey	House	Democratic	nay
Randy Weber	Texas	House	Republican	yea
Daniel Webster	Florida	House	Republican	yea
Brad Wenstrup	Ohio	House	Republican	yea
Bruce Westerman	Arkansas	House	Republican	yea